Astellas and Gedeon Richter breach ABPI code
The UK subsidiaries of Japan’s Astellas Pharma (TYO: 4503) and Hungarian drugmaker Gedeon Richter (RICHT: HB) have brought discredit upon, and reduced confidence in, the pharmaceutical industry, says trade group the Association of the British Pharmaceutical Industry (ABPI).
Both companies have been named in advertisements following breaches of the ABPI Code of Practice for the Pharmaceutical Industry. Astellas UK has been publicly reprimanded and Gedeon Richter required to issue a corrective statement.
Astellas UK – Case AUTH/2883/10/16: Following a voluntary admission about its oversight of and materials produced for two patient support programs related to Betmiga (mirabegron) and Vesicare (solifenacin succinate), Astellas was ruled in breach of the following clauses of the Code.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze